Abstract | BACKGROUND: METHODS: In this prospective Institutional Review Board (IRB)-approved study, patients with NHL and a recent computed tomography (CT) examination were eligible. Whole-body and selected single-photon emission computed tomography (SPECT) imaging was performed 1 h after intravenous injection of 99mTc-depreotide. Images were compared with CT scan findings. The radioactivity concentration of 99mTc-depreotide in abdominal/pelvic tumour sites, together with normal organs, was determined and expressed as the percentage of injected activity per gram of tissue (%IA x g). RESULTS: Paired CT and 99mTc-depreotide images for three patients with indolent and six with aggressive NHL revealed abnormal 99mTc-depreotide uptake corresponding to the tumour seen on CT in seven of these patients. In three of the patients, all known tumour sites were detected on 99mTc-depreotide images. The mean %IA x g for nine abdominal/pelvic tumour foci from four patients was found to be 0.004% (range, 0.001-0.007%). The mean tumour to bone marrow activity concentration ratio in these four patients was found to be 0.94 (range, 0.33-1.40), whereas the tumour to kidney ratio was 0.53 (range, 0.16-0.80). CONCLUSIONS: Levels of 99mTc-depreotide in tumour suggest at least the possibility of potential therapy with beta emitter-labelled SSTR peptides; however, depreotide itself appears not to be a suitable candidate as a targeting agent due to the relatively high bone marrow concentration.
|
Authors | David L Bushnell, Yusuf Menda, Mark T Madsen, Brian K Link, Daniel Kahn, Scott M Truhlar, Malik Juweid, Mary Shannon, Jeffrey S Murguia |
Journal | Nuclear medicine communications
(Nucl Med Commun)
Vol. 25
Issue 8
Pg. 839-43
(Aug 2004)
ISSN: 0143-3636 [Print] England |
PMID | 15266180
(Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article, Validation Study)
|
Chemical References |
- Organotechnetium Compounds
- Radiopharmaceuticals
- Somatostatin
- technetium Tc 99m depreotide
|
Topics |
- Humans
- Lymphoma, Non-Hodgkin
(diagnostic imaging, metabolism)
- Organotechnetium Compounds
(pharmacokinetics)
- Radiography
- Radiopharmaceuticals
(pharmacokinetics)
- Reproducibility of Results
- Sensitivity and Specificity
- Somatostatin
(analogs & derivatives, pharmacokinetics)
- Tomography, Emission-Computed, Single-Photon
(methods)
|